Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The treatment of Crohn’s disease (CD) includes not only conventional therapies, many of which are generically available, but also potent biologics, which are often reserved for patients with moderate to severe disease activity. In addition to the entrenched TNF-ɑ inhibitors, two newer biologics (Takeda’s Entyvio and, mostrecently, Janssen’s Stelara) are being used primarily in the TNF-refractory population and competing with the older biologics for earlier lines of therapy. Given this increasing competition, which will continue to intensify as additional agents launch, brand differentiation, insight into the current clinical profiles and cost basis of patients taking available brands, and identification of growth opportunities in key patient segments will be critical for market success.